Dynavax Nears Final Chapter with Sanofi Acquisition
Published on 02/05/2026 at 10:51 | Redaktion boerse-global.de
The independent journey of Dynavax Technologies on the public markets is drawing to a definitive close. The biopharmaceutical firm is in the last stages of being acquired by French pharmaceutical giant Sanofi, with final administrative procedures now underway to seal the deal.
Sanofi, operating through its subsidiary Samba Merger Sub, has set the terms for the takeover. The all-cash transaction values Dynavax at approximately $2.2 billion. Shareholders of record are entitled to receive $15.50 for each share they hold.
- Acquisition Price: $15.50 per share (cash)
- Acquiring Entity: Sanofi (via Samba Merger Sub)
- Final Day to Tender Shares: February 9, 2026, at 11:59 PM ET
- Expected Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
